Clinical trials: sponsored by Shanghai Juncell Therapeutics
Solid Tumors, Adult
A Study of GC203 TIL in Advanced Solid Tumors (NF)
This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.
- Trial name
- NCT07256756
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai Juncell Therapeutics
Melanoma
A Study of GC101 TIL in Advanced Melanoma
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
- Trial name
- MIZAR-003 (NCT06703398)
- Testing
- GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumors
A Study of GC101 TIL in Advanced Solid Tumors (TR)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with Advanced malignant solid tumors.Autologous TILs are expanded from tumor resections or biopsies and infused i.v.
- Trial name
- NCT04967833
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Juncell Therapeutics
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
A Phase Ib Study of GC101 in NSCLC
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.
- Trial name
- MIZAR-005 (NCT06473961)
- Testing
- Autologous Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Juncell Therapeutics
Gastrointestinal Tumor
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gastrointestinal tumors.
- Trial name
- NCT04960072
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Non Small Cell Lung Cancer
A Phase II Study of GC101 in NSCLC
28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.
- Trial name
- NCT07560111
- Testing
- Autologous Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Juncell Therapeutics
Pancreatic Cancer, Pancratic Ductal Adenocarcinoma
A Study of GC203 TIL in PDCA (RJ)
This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects, Tumor Infiltrating Lymphocytes
- Trial name
- NCT06828328
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Juncell Therapeutics
Solid Tumor, Adult
A Study of TIL in Advanced Solid Tumors (CZ)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v.
- Trial name
- NCT07294872
- Testing
- GC101TIL
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumor, Tumor Infiltrating Lymphocytes
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v.
- Conditions
- Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05087745
- Testing
- Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Glioma
Study of GC101 TIL in Brain Glioma (Soochow2)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v.
- Trial name
- NCT04943913
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Tumor Infiltrating Lymphocytes, Safety
A Study of GC101 TIL in Advanced Melanoma (BZ)
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy
- Trial name
- MIZAR-002 (NCT06120712)
- Testing
- GC101 TIL
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumor, Tumor Infiltrating Lymphocytes
A Study of TIL in Advanced Solid Tumors (DFGD)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT06488950
- Testing
- GC203 TIL(gene-edited TIL) or autologous TILs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Liver Cancers, Tumor Infiltrating Lymphocyte
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers.
- Conditions
- Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05098197
- Testing
- Tumor Infiltrating Lymphocyte
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Melanoma, Tumor Infiltrating Lymphocyte
A Study of GC101 TIL in Advanced Melanoma (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v.
- Conditions
- Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05098184
- Testing
- Tumor Infiltrating Lymphocyte
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Breast Cancer, Treatment Side Effects
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer.
- Conditions
- Breast Cancer, Treatment Side Effects, Advanced Breast Cancer, Effects of Immunotherapy
- Trial name
- NCT05142475
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05098171
- Testing
- Signal Switch Receptor Modified TIL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Solid Tumor, Gynecologic Cancer
A Study of GC203 TIL in Advanced Malignant Solid Tumors
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
- Conditions
- Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer
- Trial name
- KUNLUN-001 (NCT06375187)
- Testing
- Engineering Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05468307
- Testing
- Membrane Bound Cytokine Modified TIL
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Juncell Therapeutics
Tumor Infiltrating Lymphocytes, Safety
A Phase I Study of GC101 TIL in Advanced Solid Tumors
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy
- Trial name
- MIZAR-001 (NCT05417750)
- Testing
- TIL therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Juncell Therapeutics